Sylvester Comprehensive Cancer Center Study Signals Novel Option for Hard-to-Treat Kidney Cancer
July 02, 2026
July 02, 2026
MIAMI, Florida, July 2 -- The University of Miami Miller School of Medicine posted the following news:
* * *
Sylvester Comprehensive Cancer Center Study Signals Novel Option for Hard-to-Treat Kidney Cancer
Summary
* Casdatifan, a new generation HIF-2a blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer.
* Findings link treatment activity to HIF-2a biology and biomarker changes, . . .
* * *
Sylvester Comprehensive Cancer Center Study Signals Novel Option for Hard-to-Treat Kidney Cancer
Summary
* Casdatifan, a new generation HIF-2a blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer.
* Findings link treatment activity to HIF-2a biology and biomarker changes, . . .